TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33413393

Group type: EXPERIMENTAL
Intervention: Presence of RO33 genetic variant
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Multiplicity of infection (MOI)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Parasite density
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) level
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Other allelic families (K1, MAD20, FC27, 3D7)
Number of subjects: 724
Study: 33413441

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over M1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathodal tDCS over PMAs
Number of subjects: 0
Study: 33413492

Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy
Number of subjects: 96

Group type: COMPARATOR
Intervention: 10 × 3 Gy
Number of subjects: 96
Study: 33413552

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Before treatment (BT) group
Number of subjects: 93
Study: 33413574

Group type: EXPERIMENTAL
Intervention: Multiplex immunofluorescence (mIF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hierarchical linear modeling
Number of subjects: 25
Study: 33413583

Group type: EXPERIMENTAL
Intervention: Esmolol infusion for 6 hours to decrease heart rate by 20%.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Esmolol infusion for 6 hours.
Number of subjects: 9
Study: 33413596

Group type: EXPERIMENTAL
Intervention: Comprehensive family history assessment of up to four generations
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Average family history cancer risk cohort
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Family history not available cohort
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Assessment of 25 cancer genes in ACMG Secondary Findings
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Increased family history cancer risk without actionable variant
Number of subjects: 1750
Study: 33413658

Group type: EXPERIMENTAL
Intervention: Access to an evidence-based patient information resource and the PExMS-website for 4 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Access to evidence-based information alone (Control group)
Number of subjects: 55
Study: 33413664

Group type: EXPERIMENTAL
Intervention: Surgical repair and usual post-operative rehabilitation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Physiotherapist-led exercise
Number of subjects: 76
Study: 33413677

Group type: EXPERIMENTAL
Intervention: Surgical removal of endometriosis (excision or ablation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diagnostic laparoscopy alone (with a sham port to achieve blinding)
Number of subjects: 90
Study: 33413688

Group type: EXPERIMENTAL
Intervention: Mobile technology supervision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human-Centered Design (HCD) workshop
Number of subjects: 0
Study: 33413809

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 467
Study: 33413863

Group type: EXPERIMENTAL
Intervention: Cardioband tricuspid system
Number of subjects: 30
Study: 33414259

Group type: EXPERIMENTAL
Intervention: Pharmaceutical interventions (PIs) by clinical pharmacist during the PICC process
Number of subjects: 277
Study: 33414758

Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (Acthar® Gel)
Number of subjects: 0
Study: 33414828

Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg/d) tapered off by week 24
Number of subjects: 20
Study: 33414927

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 20
Study: 33415096

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33415114

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic burnout
Number of subjects: 0
Study: 33415416

Group type: EXPERIMENTAL
Intervention: Quizartinib dihydrochloride (20, 30, and 60 mg daily)
Number of subjects: 226
Study: 33415580

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 5
Study: 33415656

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) therapy for 1 month
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) therapy for 6 months
Number of subjects: 46
Study: 33415992

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33416257

Group type: EXPERIMENTAL
Intervention: Mobilization therapy (level + duration)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mobilization therapy (duration)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mobilization therapy (level)
Number of subjects: 150
Study: 33416261

Group type: EXPERIMENTAL
Intervention: Immunotherapy with checkpoint inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytotoxic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological or molecular inhibition of autophagy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer vaccines
Number of subjects: 0
Study: 33416285

Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Number of subjects: 20
Study: 33416500

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10 sessions over 2 weeks and 20 sessions over 4 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 200
Study: 33416509

Group type: EXPERIMENTAL
Intervention: e-transfer tool
Number of subjects: 4

Group type: COMPARATOR
Intervention: dictation only
Number of subjects: 4
Study: 33416995

Group type: EXPERIMENTAL
Intervention: Oral Symptom Assessment Scale (OSAS)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Demographic and performance status assessments
Number of subjects: 250
Study: 33417036

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography in T2DM patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls (HC) (n=23)
Number of subjects: 36
Study: 33417236

Group type: EXPERIMENTAL
Intervention: Experimental interventions (training, support, or both, with or without information)
Number of subjects: 2367
Study: 33417474

Group type: EXPERIMENTAL
Intervention: Risk-adapted preemptive tocilizumab (8-12 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard CRS management (LTBC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Risk-adapted preemptive tocilizumab
Number of subjects: 70
Study: 33417511

Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg once every 3 weeks) plus Ipilimumab (3 mg/kg once every 3 weeks) for four inductions, followed by Nivolumab (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.
Number of subjects: 52
Study: 33417814

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment, details not available
Number of subjects: 0
Study: 33417885

Group type: EXPERIMENTAL
Intervention: Neural embodiment promoted by sensory feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33417919

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 1834

Group type: COMPARATOR
Intervention: Delayed cord clamping
Number of subjects: 1834
Study: 33418143

Group type: EXPERIMENTAL
Intervention: Speech Therapy App (STAPP)
Number of subjects: 25
Study: 33419080

Group type: EXPERIMENTAL
Intervention: Learning Through Play Plus Dads (LTP+ Dads) intervention, 10 sessions over three months.
Number of subjects: 18
Study: 33419423

Group type: EXPERIMENTAL
Intervention: Patients with overt CS (newly diagnosed and recurrent)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Matched controls without CS
Number of subjects: 180
Study: 33419448

Group type: EXPERIMENTAL
Intervention: Iron folic acid (IFA) or long-lasting insecticide-treated bednets during ANC visit
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Out-of-pocket costs (OPC)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Time spent attending ANC
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: ANC attendance score
Number of subjects: 1736
Study: 33419900

Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Number of subjects: 1370

Group type: COMPARATOR
Intervention: New ACLF diagnostic criteria
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Future proteomic and metabolic omics analyses
Number of subjects: 1370
Study: 33419913

Group type: EXPERIMENTAL
Intervention: Sensorimotor function assessment including hop performance, muscle strength, muscle activation, hip and ankle range of motion, and postural orientation.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 3D kinematics and joint position sense evaluation (for Umeå cohort).
Number of subjects: 200
Study: 33420229

Group type: EXPERIMENTAL
Intervention: Everolimus daily orally at 10 mg for 12 weeks
Number of subjects: 24
Study: 33420629

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 71
Study: 33420642

Group type: EXPERIMENTAL
Intervention: Fluzoparib (100 mg, p.o.) after meal consumption on day-1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Omeprazole 40 mg (p.o.) under fasting condition from day-5 to day-9
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluzoparib (100 mg, p.o.) after meal consumption on day-9
Number of subjects: 16
Study: 33420678

Group type: EXPERIMENTAL
Intervention: C-Care mobile application
Number of subjects: 36
Study: 33420682

Group type: EXPERIMENTAL
Intervention: Number of antithrombotic drugs used (0 to 8, interquartile range = 3-4)
Number of subjects: 10568
Study: 33420804

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33420912

Group type: EXPERIMENTAL
Intervention: Deep learning framework
Number of subjects: 201
Study: 33420913

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33421071

Group type: EXPERIMENTAL
Intervention: Preconception cannabis use
Number of subjects: 1228
Study: 33421178

Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg and Carfilzomib 20/56 mg/m²
Number of subjects: 0
Study: 33421757

Group type: EXPERIMENTAL
Intervention: Volitional transversus abdominis activation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no transversus abdominis activation)
Number of subjects: 44
Study: 33422025

Group type: EXPERIMENTAL
Intervention: Operative treatment strategies for tibial shaft fractures (TSFs) including various surgical techniques and implant materials, with no specific dosage or duration mentioned.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Systemic perioperative antibiotic prophylaxis, local antimicrobials, and timing of soft-tissue coverage.
Number of subjects: 1000
Study: 33422084

Group type: EXPERIMENTAL
Intervention: R3™ Acetabular System with BIOLOX® Delta ceramic femoral head
Number of subjects: 175
Study: 33422139

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) at a single dose of 1 × 10
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 14
Study: 33422153

Group type: EXPERIMENTAL
Intervention: Remote-only communication with healthcare providers
Number of subjects: 88
Study: 33422398

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 128
Study: 33423113

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 242
Study: 33423806

Group type: EXPERIMENTAL
Intervention: Mixed serous and endometrioid (SER-EM-M)
Number of subjects: 934

Group type: COMPARATOR
Intervention: Pure serous (SER)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Indeterminate serous vs. endometrioid (SER-EM-I)
Number of subjects: 934
Study: 33424715

Group type: EXPERIMENTAL
Intervention: Psychological Intervention tailored for Patients with Cognitive Impairment (PIPCI), once a week for 10 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cognitive training, once a week for 10 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Psychological Intervention tailored for Patients with Cognitive Impairment (PIPCI)
Number of subjects: 120
Study: 33424755

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cryotherapy)
Number of subjects: 0
Study: 33425328

Group type: EXPERIMENTAL
Intervention: Intervention not specified; data from Community-based Household Survey (2014-2017) used for analysis.
Number of subjects: 0
Study: 33425330

Group type: EXPERIMENTAL
Intervention: Self-help groups (SHGs) members
Number of subjects: 62690
Study: 33425329

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) tool exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33425331

Group type: EXPERIMENTAL
Intervention: Health-layering of self-help groups (SHGs) with health education modules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard self-help groups (SHGs) without health education modules
Number of subjects: 0
Study: 33425333

Group type: EXPERIMENTAL
Intervention: AMANAT intervention (on-the-job, on-site nurse mentoring and training)
Number of subjects: 80
Study: 33425334

Group type: EXPERIMENTAL
Intervention: Simulation and team-training intervention
Number of subjects: 668

Group type: COMPARATOR
Intervention: Top one-third facilities (high simulation)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Maternal complication simulations
Number of subjects: 668

Group type: COMPARATOR
Intervention: Middle one-third facilities (moderate simulation)
Number of subjects: 668
Study: 33425335

Group type: EXPERIMENTAL
Intervention: Statewide maternal and child health program
Number of subjects: 10174
Study: 33425385

Group type: EXPERIMENTAL
Intervention: Earplugs and eye mask
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ocean sound
Number of subjects: 2
Study: 33425441

Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX) for 3, 21-day courses
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX)
Number of subjects: 36
Study: 33425673

Group type: EXPERIMENTAL
Intervention: Single dose of zoledronate
Number of subjects: 211

Group type: COMPARATOR
Intervention: 6-monthly dosing of zoledronate
Number of subjects: 211
Study: 33425801

Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl 0.2 mg in the fed state with a high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl 0.4 mg in the fed state with a high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl 0.4 mg in the fasted state
Number of subjects: 0
Study: 33425820

Group type: EXPERIMENTAL
Intervention: Magnetic non-invasive auricular acupuncture during eye-exam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33425931

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Health Promotion Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33425946

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33426003

Group type: EXPERIMENTAL
Intervention: Dapagliflozin added to Furosemide
Number of subjects: 0
Study: 33426008

Group type: EXPERIMENTAL
Intervention: Trimethylamine N-Oxide
Number of subjects: 0
Study: 33426066

Group type: EXPERIMENTAL
Intervention: 3D printing technology with arthroscopic surgery
Number of subjects: 21

Group type: COMPARATOR
Intervention: C-arm fluoroscopy with arthroscopic surgery
Number of subjects: 21
Study: 33426802

Group type: EXPERIMENTAL
Intervention: 10-20-30 training (high-intensity interval exercise training) for 10 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nondiabetes counterparts (ND)
Number of subjects: 12
Study: 33427211

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors with high matching score (≥50%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CDK4/6 inhibitors with low matching score (<50%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors (high matching score)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CDK4/6 inhibitors (low matching score)
Number of subjects: 40
Study: 33427685

Group type: EXPERIMENTAL
Intervention: Metformin-containing medication
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: my ePRO app
Number of subjects: 300
Study: 33427689

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 4
Study: 33427767

Group type: EXPERIMENTAL
Intervention: Just4Us intervention (counselor-navigator and text message support)
Number of subjects: 0
Study: 33427818

Group type: EXPERIMENTAL
Intervention: Intensive implementation support during the pilot phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-focus districts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formerly focus districts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall change from round 2-9 in focus districts
Number of subjects: 0
Study: 33428174

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study: 33428222

Group type: EXPERIMENTAL
Intervention: Intraoperative MRI (iMRI)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Fluorescence-guided surgery with 5-ALA
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Neuronavigation
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Intraoperative MRI (iMRI) (second trial)
Number of subjects: 322
Study: 33428248

Group type: EXPERIMENTAL
Intervention: Micra implant with concomitant AVNA
Number of subjects: 192

Group type: COMPARATOR
Intervention: Micra patients without AVNA
Number of subjects: 192
Study: 33428522

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33428559

Group type: EXPERIMENTAL
Intervention: Experiences of violence (psychological abuse, verbal abuse, emotional maltreatment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HIV clinic settings addressing verbal abuse and emotional maltreatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Peer mentoring
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard discipline practices (physical violence from caregivers and teachers)
Number of subjects: 41
Study: 33428617

Group type: EXPERIMENTAL
Intervention: Steps 1-9
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Steps 1-10
Number of subjects: 903

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Steps 1-9 with breastfeeding difficulties
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Steps 1-10 with breastfeeding difficulties
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Steps 1-9 without breastfeeding difficulties
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Steps 1-10 without breastfeeding difficulties
Number of subjects: 903
Study: 33428771

Group type: EXPERIMENTAL
Intervention: Pazopanib with a 1-hour interval before taking gastric acid suppressants (GAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pazopanib without a specified interval before taking gastric acid suppressants (GAS)
Number of subjects: 0
Study: 33429092

Group type: EXPERIMENTAL
Intervention: DETOUR procedure using TORUS stent grafts
Number of subjects: 78
Study: 33429865

Group type: EXPERIMENTAL
Intervention: Germline pathogenic/likely pathogenic variants (P/LPVs) in cancer susceptibility genes identified in patients with PDAC.
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Germline pathogenic/likely pathogenic variants (P/LPVs) in homologous recombination repair (HRR) genes identified in patients with PDAC.
Number of subjects: 549
Study: 33430634

Group type: EXPERIMENTAL
Intervention: NCCT±CTA alone in the early window (n=332)
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: NCCT±CTA and CTP in the early window (n=373)
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Extended window endovascular stroke therapy
Number of subjects: 2008
Study: 33430796

Group type: EXPERIMENTAL
Intervention: VARIZIG
Number of subjects: 303
Study: 33430807

Group type: EXPERIMENTAL
Intervention: Prospective measure of Post-Traumatic Growth (PTG)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Retrospective measure of Post-Traumatic Growth (PTG)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: PTSD scale administered at five-month follow-up
Number of subjects: 187
Study: 33430816

Group type: EXPERIMENTAL
Intervention: Close Collaboration with Parents intervention
Number of subjects: 170
Study: 33430820

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 28
Study: 33430930

Group type: EXPERIMENTAL
Intervention: Diaphragm electrical activity (EAdi) monitoring after intubation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sedative agents (propofol and fentanyl)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Reverse triggering
Number of subjects: 69

Group type: COMPARATOR
Intervention: General severity, oxygenation, renal and hepatic function, reason for intubation
Number of subjects: 69
Study: 33431018

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) Antipsychotic Medication Decision Aid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study: 33431027

Group type: EXPERIMENTAL
Intervention: Brain CareNotes (BCN) mobile telehealth system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care comparator
Number of subjects: 60
Study: 33431248

Group type: EXPERIMENTAL
Intervention: Life satisfaction
Number of subjects: 1904

Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Moderate to Severe depression profile
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Mild depression profile
Number of subjects: 1904
Study: 33431488

Group type: EXPERIMENTAL
Intervention: Disease-specific guideline deviation for atrial fibrillation, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disorder, depression, diabetes, dyslipidaemia, hypertension and ischaemic heart disease.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combined-care guideline deviation.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 204